Jitendra – Page 16 – Scilex Holding

27 Apr

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.

April 26, 2022
Posted by Jitendra

PALO ALTO, CA. April 27, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

26 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

25 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

25 Apr

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies

April 25, 2022
Posted by Jitendra

PALO ALTO, CA. April 25, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

25 Apr

Press Release

Dr. Henry Ji, Sorrento Therapeutics’ Chairman And Ceo And Scilex Holding Company’s Executive Chairman, To Present At The B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)

May 3, 2022
Posted by Jitendra

San Diego, CA and Palo Alto, CA., April 25, 2022 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive...

13 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

12 Apr

Press Release

Scilex Holding Company a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

April 13, 2022
Posted by Jitendra

PALO ALTO, CA. April 12, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

11 Apr

SEC FIlings